PDB21 Safety and Efficacy Comparison between Insulin Degludec and Insulin Glargine

Abstract

To compare the available evidence on the clinical safety and efficacy of insulin degludec versus insulin glargine for diabetes mellitus patients. Studies were obtained from electronic search of PubMed. We include randomized controlled trials comparing insulin degludec (plus minas other hypoglycemic agents) or insulin glargine (plus minus other hypoglycemic agents). Six randomized studies comparing insulin degludec to insulin glargine were identified. In these trials, 2609 patients were randomized to insulin degludedc and 1296 patients were randomized to insulin glargine. Duration of these included study were between 16 weeks to 104 weeks. HbA1c reduction from baseline to the study ends did not differ statistically significantly between insulin degludec group and insulin glargine group. The result showed occurrence rate of overall hypoglycemia event rate for insulin degludec group was smaller than insulin glargine group with incidence rate ratio 0.90[0.86; 0.93]. However, occurrence rate of severe hypoglycemia event did not differ statistically significantly between insulin degludec group and insulin glargine group. Our analysis suggests that there is no statistically relevant difference between insulin degludec and insulin glargine in efficacy point of view, however; insulin degludec is better than insulin glargine for safety point of view.